Biogen hires former Sanofi head Viehbacher as CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Biogen (BIIB) new CEO could be 'just what BIIB needs'
November 10, 2022 1:04 PM ESTBiogen (NASDAQ: BIIB) announced that the former CEO of Sanofi, Christopher Viehbacher, will take over as its President, CEO, and member of the Board of Directors effective on November 14.
Following the announcement, Cowen analyst Phil Nadeau told investors in a note that although his tenure at Sanofi ended abruptly, a strong CEO personality aligned with... More
